UNSPSC 51384519: Vedaprofen

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C19H22O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OKX88EO7OI, chemically known as 1-naphthaleneacetic acid, 4-cyclohexyl-alpha-methyl-, (+-)- but generally known as vedaprofen, which bears US NIH Compound Identifier 72158. European Medicines Agency schedules Vedaprofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00031MIG.

UNSPSC 51384519 Vedaprofen, a Commodity code, sees minimal recent state and local procurement activity aligned with its nominal scope. The three recent opportunities tagged under this code—a Seminole County naloxone and drug deactivation systems procurement, a Texas HHS Request for Information on direct-to-manufacturer prescriptions, and a Minnesota Multistate Cooperative Purchasing Alliance RFP for generic multi-source pharmaceuticals—represent pharmaceutical supply and pharmacy benefit management work that diverges significantly from vedaprofen, a specific veterinary nonsteroidal anti-inflammatory drug. State and local governments are using this code to solicit pharmaceutical procurement support broadly, including naloxone distribution, pharmacy benefit program infrastructure, and generic drug supply agreements, but the code appears misapplied to capture these activities rather than reflecting genuine vedaprofen demand.

Activity is concentrated in three states with distinct procurement mechanisms: Florida (Seminole County conducting a direct IFB for naloxone and drug deactivation systems with a response date of July 26, 2023), Texas (the state HHS Commission issuing an RFI on April 3, 2026 to explore direct-to-manufacturer prescription programs), and Minnesota (MMCAP administering a cooperative purchasing RFP for generic pharmaceuticals due March 26, 2026, available to multiple state and local participants including Oregon). The issuing bodies span county health departments, state health and human services agencies, and interstate cooperative purchasing alliances. No recent opportunities reflect actual vedaprofen procurement, and the code shows little relevant market signal for vendors pursuing veterinary pharmaceutical supply contracts at the state and local level.